Butyric Acid Market Size Worth USD 634.55 Million by 2034 Driven by Rising Demand Across Animal Feed and Pharmaceutical Industries
According to Precedence Research, the global butyric acid market size is expected to be worth over USD 634.55 million by 2034, up from USD 422.13 million in 2025. The market is growing at a CAGR of 4.60% from 2025 to 2034. The industry growth driven by increasing demand across industries such as animal feed, pharmaceuticals, food & beverages, and chemicals.
Ottawa, May 05, 2025 (GLOBE NEWSWIRE) -- The global butyric acid market size has been calculated at USD 422.13 million in 2025 and is estimated to rise from USD 440.28 million in 2026 to USD 634.55 million by 2034. The large application of butyric acid in various industries drives the growth of the market. The Asia Pacific butyric acid market size accounted for USD 188.0 million in 2025 and is expanding at a CAGR of 5% during the forecast period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@
Butyric Acid Market Key Highlights (2024)
Asia Pacific emerged as the leading market, commanding a robust 44.4% share of the global butyric acid market.
The renewable segment dominated the product landscape, securing an impressive 65.2% market share, reflecting growing demand for sustainable solutions.
The animal feed segment held the largest share, accounting for 54.22% of the market, driven by increasing livestock production and focus on animal health.
Calcium butyrate stood out among derivatives, contributing a significant 45.1% share to the overall market, supported by its rising adoption in the feed industry.
Butyric Acid Market Revenue by Product 2022 to 2024 (USD Million)
Product
2022
2023
2024
Renewable
243.2
253.3
264.1
Synthetic
131.0
135.8
141.0
Butyric Acid Market Revenue by Application, 2022 to 2024 (USD Million)
Application
2022
2023
2024
Chemical Intermediates
59.9
62.5
65.3
Animal Feed
203.9
211.5
219.6
Pharmaceuticals
43.0
44.8
46.7
Food & Flavors
44.9
47.0
49.2
Others
22.5
23.3
24.2
This Report is Readily Available for Immediate Delivery | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2631
Butyric Acid Market Overview
A chemical component called butyric acid is used to make a variety of goods, including plastics, coatings, food additives, perfumes, and medications. It is also well-known for its use as a wheat grain preservative and in medicine. At the industrial level, butyric acid is mostly produced by chemical synthesis. One molecule that shows promise for meeting the energy demands of the future is butyric acid.
In August 2024, Fonterra and Superbrewed Food announced their collaboration to advance postbiotic-protein rich. In May 2024, NutraShure announced the launch of BIOMEnd which is a butyrate form that is designed to resolve the solubility and palatability issues found in conventional butyrate components.
Contemporary Inventions by the Flagship Companies in 2024
Sr. No.
Name of the Company
Recent Invention
1.
Perstorp Holding AB
A new state-of-the-art Penta Chemicals Plant in Western India.
2.
OQ Chemicals GmbH
Heptanoic Acid Production in Germany
3.
Eastman Chemical Company
Eastman™ Butyric acid (C3H7COOH)
A new food/feed grade butyric acid
4.
Palital Feed Additives B.V.
Rumen-Ready® to stimulate rumen redevelopment in dairy cows
Make Informed Decisions — Unlock Full Analysis@ https://www.precedenceresearch.com/butyric-acid-market
Major Breakthroughs in Butyric Acid Industry:
In May 2024, through its ability to restore the function of immune cells that restrict the formation of disease-causing antibodies, butyric acid from gut bacteria or supplementation with its salt form butyrate may prove to be a promising therapy for myasthenia gravis (MG). This is in line with the results of a recent study conducted on mice and human cells.
In February 2024, researchers from the Grand Forks Human Nutrition Research Center, the University of Massachusetts, and the USDA's Agricultural Research Service investigated how butyrate, a short-chain fatty acid present in the gut, inhibits the development of several colon cancer cells in a lab setting.
Growth Factors and Opportunities in the Butyric Acid Market
Growing demand for biofuels: although butyric acid has several applications in various sectors, its usage as a precursor to biofuels is now of significant interest. Research has recently focused on alternative fuel sources due to rising petroleum costs, a steadily declining supply of petroleum, and an increasing need for sustainable energy sources.
Usage in disease treatment: Diarrhea, intestinal inflammations, functional abnormalities, dysbiosis, and illnesses following surgery or chemotherapy are among the gastrointestinal ailments that butyric acid is used to treat and prevent from getting worse.
Growing demand for processed food: One food additive that is utilized as a food preservative, taste enhancer, and food flavoring agent is butyric acid. Many fermented foods and dairy products naturally contain it. The FDA has classified butyric acid as generally recognized as safe (GRAS), meaning that it is safe to eat when it is present in food.
Butyric Acid Market Report Scope
Report Coverage
Details
CAGR 2025 to 2034
4.60%
Market Size in 2024
USD 405.11 Million
Market Size in 2025
USD 422.13 Million
Market Size by 2034
USD 634.55 Million
Prominent Region in 2024
Asia Pacific
Base Year
2024
Forecast Year
2025 to 2034
Segments Covered
Product, Application, Derivatives, and Region
Regions Covered
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa
Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription
What is the Market Size of the Asia Pacific Butyric Acid?
According to Precedence Research, the Asia Pacific butyric acid market size was estimated at USD 179.7 million in 2024 and is projected to be worth around USD 290.9 million by 2034, growing at a CAGR of 5% from 2025 to 2034.
Set up a meeting at your convenience to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting
Growing Food & Supplement Demand, Asia Pacific to Sustain as a Leader
Asia Pacific dominated the butyric acid market in 2024 due to the fast-growing food and beverage (F&B) and cattle sectors in the area. The need for animal feed additives like butyric acid to increase livestock production and satisfy the growing demands for protein intake is driven by nations like China and India, which have sizable agricultural sectors and expanding populations.
This need is being further supported by the region's growing emphasis on enhancing animal health and implementing sustainable agricultural methods. The market's growth is further aided by the strong expansion of the personal care and pharmaceutical sectors in Asia Pacific, where butyric acid is found in a variety of cosmetic and medicinal applications.
The presence of major manufacturers in the area and favorable government legislation supporting bio-based chemicals are also contributing significantly to the market's expansion.
One of the biggest producers of cattle worldwide is China. WAICENT reports that it maintains around 50% of the world's pig population, 20% of its goats and poultry, and 15% of its buffaloes.
India is the nation with the largest livestock population in the world, with 537 million animals. India is the world's largest producer of milk and has a wealth of animal resources that are both a dependable source of food and a major economic contributor. The livestock industry's continually growing contribution to the agriculture sector throughout time is evidence of its growing importance in the Indian economy. From 2022 to 2023, the country will produce 230.58 million tons of milk. The country will generate 138.38 billion eggs between 2022 and 2023. From 2022 to 2023, the country will produce 9.77 million tons of beef. The total amount of wool produced in the country is 33.61 million kg.
New Product Range of TCI Chemicals in 2024 in India
Sr. No.
Name of the Product
Product Category
o-Nitrobenzyl Photolabile Bifunctional Linkers
Synthetic Chemistry
n-Type SAM Forming Agent Enabling Efficient Perovskite Solar Cell: PANDI
Materials Science
Phenylphenothiazine (PTH) Derivatives
Organic Semiconductors
Ready-to-Use Cationic Polymer Solution for Gene Transfection
Life Science
High Demand for Packaged Foods: North America to Grow at the Fastest Rate
North America's butyric acid market is estimated to grow significantly during the forecast period. Numerous factors are contributing to the market's expansion in North America. The existence of indigenous chemical industry companies like Eastman Chemical and the region's well-established food and pharmaceutical sectors are important drivers.
In the US and Canada, urbanization and increased disposable income are major drivers of these businesses' growth. For example, the US's disposable personal income increased by 1% each month in January 2024. Convenient packaged food products are becoming more and more popular due to hectic work schedules and rising disposable money. Butyric acid, used to retain moisture in packaged food and improve food taste or smell, is necessary due to the region's expanding food sector.
Butyric acid is also widely employed in the manufacturing of feed, especially in feed additives and premixes for pets and cattle. North American feed mills are major butyric acid users, which fuels the market's expansion. Butyric acid is also used by the pharmaceutical industry to produce some drugs and as a drug intermediary.
Ultra-processed food consumption in American homes is rising more quickly than it is outside the house. According to a recent survey conducted by experts at the Johns Hopkins Bloomberg School of Public Health, ultra-processed foods account for almost half of the calories that individuals in the United States consume at home.
The constant expansion of the world economy, the ongoing depreciation of the US currency, and the demand from overseas markets for specific cuts and sections of meat from the sizable US market are all factors contributing to the anticipated increase in U.S. red meat and poultry exports during the next ten years.
The United States:
In March 2025, Johnson & Johnson announced a $55 billion investment in U.S. healthcare operations over the next four years, a 25% increase from the previous year.
In April 2024, Eastman Chemical Company in North America announced a price increase for various products, such as Eastman™ glacial acetic acid and Eastman™ dilute acetic acid.
Butyric Acid Market Segmentation Analysis
By Product Analysis
The renewable segment held the largest share of the butyric acid market in 2024. Manufacturing of biofuels and bioplastics. Renewable biomass sources, including corn, sugar cane, and lignocellulosic materials, can be fermented to create butyric acid. This makes it an ideal feedstock for the development of biofuels, which emit less carbon dioxide than conventional fossil fuels and are renewable.
Butyric acid is a crucial component in the creation of bioplastics, which come from renewable biomass sources and may either be composted or biodegraded. The market increase is driven by the provision of an alternative to conventional plastics.
By Application Analysis
The animal feed segment dominated the butyric acid market and is expected to grow at the fastest rate during the forecast period. Because it enhances food absorption and supports intestinal health, butyric acid is crucial in animal nutrition. Monogastric animals, such as pigs and chickens, who are unable to produce enough butyric acid in their digestive systems, benefit greatly from its presence in animal feed. However, butyric acid enhances gut health by encouraging healthy microbiota, reducing the frequency of gastrointestinal disorders, and improving animal performance in general.
Higher-quality meat and dairy products, more feed efficiency, and quicker development rates are the outcomes of this. The livestock business is under pressure to effectively produce more high-quality animal products due to the growing global population and the increased demand for diets high in protein. The usage of butyric acid in feed formulations has increased as a result of the increased focus on animal nutrition and health.
Related Topics You May Find Useful:
Boric Acid Market Size accounted for USD 779.17 million in 2024 and is predicted to reach around USD 1157.73 million by 2034, growing at a CAGR of 4.04% from 2024 to 2034.
Polylactic Acid Market Size was calculated at USD 968.74 million in 2024 and is predicted to increase from USD 1,121.69 million in 2025 to approximately USD 3,864.79 million by 2034, expanding at a CAGR of 14.73% from 2025 to 2034.
Lactic Acid Market Size is estimated at USD 4.07 billion in 2024 and is anticipated to reach around USD 9.36 billion by 2034, expanding at a CAGR of 8.70% from 2024 to 2034.
Purified Terephthalic Acid Market Size is projected to be worth around USD 80.05 billion by 2034 from USD 49 billion in 2024, at a CAGR of 5.03% from 2024 to 2034.
Sulfuric Acid Market Size accounted for USD 15.56 billion in 2024 and is expected to be worth around USD 33.90 billion by 2034, at a CAGR of 8.1% from 2024 to 2034.
Ferulic Acid Market Size is estimated at USD 77.89 million in 2024 and is anticipated to reach around USD 150.38 million by 2034, expanding at a CAGR of 6.80% from 2024 to 2034.
Acetic Acid Market Size is estimated at USD 21.77 billion in 2024 and is anticipated to reach around USD 36.14 billion by 2034, expanding at a CAGR of 5.20% from 2024 to 2034.
Butyric Acid Market Top Companies:
Eastman Chemical Company
Blue Marble Biomaterials LLC
Oxea GmbH
Tokyo Chemical Industry Co. Ltd.
Perstorp Holding AB
Snowco Industrial Co. Ltd
Beijing Huamaoyuan Fragrance Flavor Co. Ltd.
What is Going Around the Globe?
In May 2024, NutraShure introduced BIOMEnd, a butyrate formulation intended to address the solubility and palatability problems associated with conventional butyrate components. According to the business, L-Lysine Butyrate, the l-lysine salt of butyric acid, is included in BIOMEnd and provides total solubility in a liquid solution.
In May 2024, Biomend was introduced by NutraShure Distribution, LLC, a distributor and supplier of ingredients in the functional food and beverage and dietary supplement industries. The component of Biomend is butyrate, a short-chain fatty acid with four carbons.
In October 2023, Lowa-based ButiShield, a novel encapsulated version of calcium butyrate from Kemin Industries, supports the strength and integrity of the intestinal wall, hence strengthening gut health overall. The butyric acid is encapsulated in the ingredient utilizing exclusive MicroPEARLS spray freezing technology.
The Butyric Acid Market report categorizes into the following segments and subsegments:
By Product
Renewable
Synthetic
By Application
Chemical Intermediates
Animal Feed
Pharmaceuticals
Perfumes
Food and Flavors
By Derivatives
Sodium Butyrate
Calcium Butyrate
Others
By Region
North America
U.S.
Canada
Asia Pacific
China
Japan
India
South Korea
Thailand
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
UAE
Saudi Arabia
Kuwait
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2631
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344
Precedence Research offers exclusive subscription services designed to provide in-depth data and analytics insights. With a subscription, you gain access to a comprehensive suite of statistical resources, market intelligence, and research tools tailored to your business needs. Whether you're looking for industry trends, competitive analysis, or future market projections, our subscription plans ensure you stay ahead with reliable, up-to-date information.
Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription
About Us
Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Web: https://www.precedenceresearch.com
Our Trusted Data Partners:
Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor
Get Recent News:
https://www.precedenceresearch.com/news
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
30 minutes ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
PingPong Expands Leading B2B Cross-Border Payments Platform Into Malaysia, Further Unlocking Southeast Asia For Enterprise Clients
PingPong has been granted a Money Services Business Licence Class B from Malaysia's central bank, Bank Negara Malaysia, unlocking a USD $445 billion economy for enterprises, financial institutions, and SaaS companies expanding into and out of Malaysia. This follows PingPong's recent expansion into Indonesia and existing presence in Vietnam, Thailand, Singapore, and the Philippines, further expanding PingPong's comprehensive portfolio of over 60 global licences. KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- PingPong, the world-leading provider of cross-border embedded payment solutions for enterprises, is pleased to announce that it has been granted a Money Services Business Licence from Malaysia's central bank, Bank Negara Malaysia. This latest licence further enhances PingPong's extensive portfolio of over 60 global licences, unlocking even more cross-border opportunities for enterprises on PingPong's platform. Malaysia offers significant growth opportunities for enterprises looking to scale in Southeast Asia. Its GDP is expected to reach $445 billion USD by the end of 2025 and grow by 33% by 2030, reaching $600 billion USD. International trade is a significant part of Malaysia's wealth, valued at 132% of GDP in 2023. Financial services and fintech companies are thriving across Southeast Asia, with Malaysia emerging as a key player. The country ranks third in the region in terms of the number of fintech companies it has, and it is poised for significant growth. Malaysia's fintech sector is projected to double, from $54 billion USD in 2025 to $111 billion USD by 2030, reflecting a robust compound annual growth rate (CAGR) of 16%. Its strategic location, high digital adoption rate, and robust financial sector have made it one of the key growing countries in Southeast Asia. Jianqin Shu, Partner and APAC General Manager at PingPong, said, "As one of the most strategically positioned and rapidly growing economies in Southeast Asia, Malaysia presents an incredible opportunity for enterprises scaling their global operations. Securing a Money Services Business licence positions PingPong at the heart of this growth, empowering us to support Malaysia's expanding fintech and financial services ecosystem, meeting the rising demand for efficient, compliant cross-border payment solutions. This milestone enables us to extend our global reach further and provide enterprises with end-to-end, one-stop payment services." This approval from Bank Negara Malaysia further adds to PingPong's significant portfolio of over 60 global licences across the United States, EU, UK, Hong Kong, mainland China, Canada, Australia, Japan, Singapore, Indonesia and other countries and regions worldwide. About us PingPong was founded in New York in 2015, with the goal of solving the immense challenge of scaling enterprise businesses globally. Fast forward to today, and PingPong has become one of the world's leading global cross-border payments platforms, processing more than $250 billion USD. Our API-first cross-border payments platform integrates with enterprises to send, manage, and receive money faster on a global scale. PingPong currently has 37 offices in 15 countries and 1,500 employees. Our international presence helps businesses solve complex payment needs in every major economy across all time zones. Logo - Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Electric Motors Market Share Expected to Grow $206.4 Billion by 2029
Delray Beach, FL, June 01, 2025 (GLOBE NEWSWIRE) -- The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during forecast period. Electric motors market is driven mainly by Increasing demand for HVAC systems among residential, commercial, and industrial end-users, growing demand for electric motors in manufacturing industries, and rising demand for energy-efficient motors. The electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market. Download PDF Brochure: List of Key Players in Electric Motors Market: ABB (Switzerland) Siemens (Germany) WEG (Brazil) Wolong Electric (China) NIDEC CORPORATION (Japan) Drivers, Opportunities and Challenges in Electric Motors Market: Driver: Increasing demand for HVAC systems in residential, commercial, and industrial sectors Restraint: Fluctuating prices of raw materials Opportunity: Transition in the global automotive industry toward electric vehicles Challenge: Shortage of components and supply chain issues Electric mobility is making a huge transition in the global automobile industry. The proactive efforts for the decarbonization of society in Europe are driven by the ever-increasing share of electric motors in the market. Advancements in battery technologies have reduced costs of batteries and improved the charging speed of the batteries. The increase in government support by providing redemptions on tax and incentives for promoting eco-friendly electric vehicles through electric motors are also acts of opportunities for the growth of the electric motors market. As per the IEA, it is revealed that 50% of global passenger electric vehicles should come from China in the year 2025. Many governments worldwide are implementing policies and incentives to promote the adoption of electric vehicles as part of efforts to reduce greenhouse gas emissions and combat climate change. These policies include subsidies for EV purchases, tax incentives, and stricter emissions regulations, all of which are accelerating the transition to electric mobility and, consequently, increasing demand for electric vehicle motor market. The rapid growth of the EV market has led to the construction of new manufacturing facilities dedicated to producing electric vehicles and their components, including electric motors. Major automakers and new EV startups are investing heavily in scaling up production, which includes securing a reliable supply of electric motors. the growing demand for electric vehicles is a major driver of demand for electric motors. The transition to electric mobility, driven by technological advancements, government policies, and consumer preferences, is creating a significant and expanding market for electric motors across a wide range of vehicle types and applications. As the EV market continues to grow, the demand for efficient, powerful, and innovative electric motors will remain strong.. Request Sample Pages: Asia Pacific region to be the largest electric motors market Asia Pacific is expected to dominate the global electric motor market size between 2024–2029, followed by Europe and North America. The urban population growth drives demand for infrastructure, including commercial buildings, residential complexes, and public utilities, all of which rely heavily on electric motors for HVAC systems, elevators, water treatment, etc are the reasons for the region's significant market size. Countries such as China and India are driving demand, supported by government initiatives promoting industrial automation and renewable energy adoption. The region's large water treatment plants and increasing electric vehicle manufacturing add to the demand for high-power motors. Moreover, improving motor efficiency and compact high-density designs also increase the market further. This is driving the electric motor market size in the Asia Pacific region. Related Reports: Brushless DC Motor Market - Global Forecast to 2028 Energy Efficient Motor Market - Global Forecast to 2028 CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website:
